PolyPeptide H1 FY26 EBITDA more than doubled to EUR 49.09 million; revenue rises 41.6% to EUR 236.63 million

Reuters2026/08/13 05:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PolyPeptide revenue climbed 41.6% to EUR 236.6 million in H1 2026, driven primarily by 72.7% growth in metabolic therapeutics.
EBITDA more than doubled to EUR 49.1 million, lifting the EBITDA margin to 20.7% from 2.7% a year earlier.
Net income swung to a profit of EUR 9.1 million, while basic EPS turned positive to EUR 0.28.
Operating cash flow fell 49.2% to EUR 25.2 million on higher receivables due to revenue phasing; capex eased 10.4% to EUR 41.3 million.
2026 guidance was raised to 25-30% revenue growth with a high-teens EBITDA margin, citing strong H1 momentum and Braine-l’Alleud running at target utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2381884_en) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PolyPeptide H1 FY26 EBITDA more than doubled to EUR 49.09 million; revenue rises 41.6% to EUR 236.63 million

You may also like

Crypto prices